deucravacitinib
bms
['#1117', 'lupus', 'ease,(-please),(-disease),(-incrrease),(-decrease)', 'deucra']
#acr22 plenary ii abstr#1117 phase 2 results +ve in #lupus! patients (65% white) on deucravacitinib, tyk2-i had more sri-4 response rates vs pbo. pbo:34.4%; deuc 3 mg bid:58.2%, deuc 6 mg bid:49.5%, deuc 12 mg qd:44.9%. no major safety, slight increase in oral herpes 
Rheumatologist. Interested in B-cells, Lupus, Sjogren, Pre-Connective Tissue Disease, Tennis, Running & Travelling ??